Breaking News

Tweet TWEET

MGC Diagnostics Corporation Announces National Jewish Health Selects the Company as Preferred Provider for Cardiopulmonary

   MGC Diagnostics Corporation Announces National Jewish Health Selects the
 Company as Preferred Provider for Cardiopulmonary Diagnostic Instrumentation

PR Newswire

SAINT PAUL, Minn., Feb. 5, 2013

SAINT PAUL, Minn., Feb. 5, 2013 /PRNewswire/ --MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
company, today announced that National Jewish Health has selected MGC
Diagnostics as its preferred provider of cardiopulmonary diagnostic
instrumentation. Based in Denver, Colorado, National Jewish Health is known
worldwide for treatment of patients with respiratory, cardiac, immune and
related disorders, and for groundbreaking medical research. National Jewish
Health has been ranked by U.S.News & World Report as the number one
respiratory hospital in the nation for the past 15 consecutive years. Founded
in 1899 as a nonprofit hospital, National Jewish Health remains the only
facility in the world dedicated exclusively to these disorders.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics has shipped a new fleet of cardiorespiratory devices;
including body plethysmography, gas exchange and spirometer systems to the
National Jewish Health main campus in Denver. Additionally, the Company is
providing a comprehensive electronic medical interface, extending security and
accessibility of cardiorespiratory patient data throughout the National Jewish
Health network.

MGC Diagnostics, ranked 'Best-In-Class' over a two year trend by MD Buyline's
User Satisfaction Report^™, is focused on providing unmatched service and
support, relentlessly making improvements, and anticipating and solving unmet
needs.

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC
Diagnostics, commented "MGC Diagnostics is pleased to have been selected by
National Jewish Health, one of the world's leading medical research and
treatment centers. We believe this win validates our technical innovation in
cardiorespiratory health and our ability to provide leading medical facilities
seamless communications with electronic medical records critical to improved
workflows. We are excited to provide long term solutions that will assist them
in maintaining their market leading status in respiratory care."

About National Jewish Health

National Jewish Health is known worldwide for treatment of patients with
respiratory, cardiac, immune and related disorders, and for groundbreaking
medical research. Founded in 1899 as a nonprofit hospital, National Jewish
Health remains the only facility in the world dedicated exclusively to these
disorders. Since 1998, U.S. News & World Report has ranked National Jewish
Health the number one respiratory hospital in the nation.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. MGC Diagnostics develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provides solutions for disease
detection, integrated care, and wellness across the spectrum of
cardiorespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward−looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward−looking
statements, the Company claims the protection of the safe harbor for
forward−looking statements contained in federal securities laws. These
forward−looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward−looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.

Contact:    Gregg O. Lehman, Ph.D.         Joe Dorame, Robert Blum,
                                                 Joe Diaz
            MGC Diagnostics Corporation         Lytham Partners, LLC
            Chief Executive Officer (602) 889-9700
            (651)                                   mgcd@lythampartners.com
            484-4874

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com